Wockhardt Limited (WOCKPHARMA) — Announcement | 11 June 2026

Wockhardt announced its US launch strategy for Zaynich, a novel antibiotic targeting carbapenem-resistant infections with 96.8% cure rates, backed by strong clinical data and a $1.5-2 billion global revenue potential. Management emphasized pricing at $1,200-$1,500/day, 75-80% discounts in India, and a 'hockey stick' growth trajectory after 12-18 months, supported by in-house US commercial capabilities and partnerships. The filing highlights strategic focus on high-margin antibiotic innovation, PLI scheme benefits, and exiting unprofitable US generics to fund R&D, positioning Wockhardt as a leader in next-generation antibiotics amid rising resistance threats.